Abstract: The invention concerns an endovascular implant comprising a biodegradable material and having a tubular main body which is open at the ends and which is dilatable from an unexpanded condition into an expanded condition. The implant is so designed that when the implant in the expanded condition is subjected to a radially acting compression pressure in the range of between 5 and 30 kPa (0.05-0.3 bar) a cross-sectional area of the implant is reduced to 70% or less of the original cross-sectional area, or an internal volume of the implant is reduced to 70% or less of the original internal volume.

Abstract: The invention relates to a medical implant made of a metallic material. After fulfilling its temporary support function, the implant is degraded by corrosion at a predetermined rate. Negative long-term effects are thus avoided.

Abstract: An endoprosthesis includes a carrier structure which contains a metallic material. The metallic material contains a magnesium alloy of the following composition: magnesium: >90%, yttrium: 3.7%-5.5%, rare earths: 1.5%-4.4% and balance: <1%.

Abstract: The invention relates to a medical implant made of a metallic material. After fulfilling its temporary support function, the implant is degraded by corrosion at a predetermined rate. Negative long-term effects are thus avoided.

Abstract: The invention relates to a medical implant made of a metallic material. After fulfilling its temporary support function, the implant is degraded by corrosion at a predetermined rate. Negative long-term effects are thus avoided.

Abstract: The invention relates to a medical implant made of a metallic material. After fulfilling its temporary support function, the implant is degraded by corrosion at a predetermined rate. Negative long-term effects are thus avoided.

Abstract: A method of treating a patient includes the medical use of one or more of the elements from the group yttrium, neodymium and zirconium, pharmaceutical formulations which contain said elements and implants which are at least region-wise made up of such formulations. It has been found inter alia that a formulation containing one or more of the elements has an action of inhibiting the proliferation of human smooth muscle cells.

Abstract: A method of treating a patient includes the medical use of one or more of the elements from the group yttrium, neodymium and zirconium, pharmaceutical formulations which contain said elements and implants which are at least region-wise made up of such formulations. It has been found inter alia that a formulation containing one or more of the elements has an action of inhibiting the proliferation of human smooth muscle cells.

Abstract: The aim of the invention is to provide an implant for releasing an active substance into a vessel through which a body medium flows. This aim is achieved by the inventive implant for releasing an active substance into a vessel through which a body medium flows. Said implant comprises a base that consists of a biodegradable material as the carrier of the active substance to be released. The body medium flows around said base on the inside and/or outside thereof.

Abstract: The invention relates to a radio-opaque marker for medical implants. Said marker contains between 10 and 90 weight percent of a biodegradable base component, between 10 and 90 weight percent of one or more radio-opaque elements from the group containing I, Au, Ta, Y, Nb, Mo, Ru, Rh, Ba, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Hf, Ta, W, Re, Os, Ir and Bi as a marker component and 10 weight percent oF residual components, the aforementioned components amounting to 100 weight percent.

Abstract: A method of treating a patient includes the medical use of one or more of the elements from the group yttrium, neodymium and zirconium, pharmaceutical formulations which contain said elements and implants which are at least region-wise made up of such formulations. It has been found inter alia that a formulation containing one or more of the elements has an action of inhibiting the proliferation of human smooth muscle cells.

Abstract: A stent comprises a tubular base body which is open on the front sides thereof and has a peripheral wall that is at least partially covered with a coating system consisting of at least one polymer carrier and at least one pharmacologically active substance, which is released into the surrounding tissue once the stent has been implanted in the human or animal body. The invention creates a coating system which enables an optimum local application of the active ingredient. A concentration of the substance, a morphological structure of the carrier(s), a material modification of the carrier(s), and/or a layer thickness of the carrier(s), are predetermined in the longitudinal direction of the stent, in such a way that the elution varies locally in the longitudinal direction of the stent and is determined according to the pathophysiological and/or rheological conditions to be expected during the application.

Abstract: The invention concerns an endovascular implant comprising a biodegradable material and having a tubular main body which is open at the ends and which is dilatable from an unexpanded condition into an expanded condition. The implant is so designed that when the implant in the expanded condition is subjected to a radially acting compression pressure in the range of between 5 and 30 kPa (0.05-0.3 bar) a cross-sectional area of the implant is reduced to 70% or less of the original cross-sectional area, or an internal volume of the implant is reduced to 70% or less of the original internal volume.

Abstract: The invention concerns inter alia an implant for vessel ligature, the implant which comprises an alloy, wherein the alloy is at least partially biodegradable, and wherein the alloy comprises: greater than 87% magnesium; from about 3% to about 6% yttrium; from about 1% to about 5% lanthanide; and a balance of about 0.0% to about 2%.

Abstract: An in vivo, decomposable medical implant is provided and comprises a metal material that contains, as a main alloying constituent, tungsten or a metal from the group rhenium, osmium, and molybdenum. The method for decomposing the implant, via corrosion in a bio system, includes the step of changing the pH level of the bio system, at least at the site of the implant, from a corrosion-inhibiting level to a corrosion-promoting level.

Abstract: The invention concerns an endovascular implant for the application of an active substance into the media 22 of a blood vessel and two processes for the production thereof. A base body 42 of the implant has at least in portion-wise manner at a surface 40 which is towards the blood vessel, a plurality of microdevices 10 for injection of the active substance. Each microdevice 10 includes on the one hand at least one microcannula 38 which is raised out of the surface 40 of the implant to such an extent that, when the implant bears against a wall 12 of the blood vessel in surface contact, the microcannula penetrates into the media 22 of the blood vessel, and on the other hand at least one active substance deposit 36 which is in communication with at least one microcannula 38.

Abstract: The invention concerns an endoprosthesis comprising a carrier structure which contains a metallic material wherein the metallic material contains a magnesium alloy of the following composition: magnesium: >90%, yttrium: 3.7%-5.5%, rare earths: 1.5%-4.4% and balance: <1%.

Abstract: The invention concerns an implantable stent (10) with an at least portion-wise polymeric coating (16). The coating material is admittedly intended to bond to known materials but by virtue of its properties it is intended to enjoy improved compatibility and reduce inflammatory and proliferative processes which can lead to restenosis. That is achieved in that the polymeric coating (16) in the implantable condition after production and sterilization contains poly-L-lactide of a mean molecular weight of more than 200 kDa.

Abstract: The invention relates to a medical implant made of a metallic material. After fulfilling its temporary support function, the implant is degraded by corrosion at a predetermined rate. Negative long-term effects are thus avoided.